Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Healthcare LLC

Adrian Funke

Torsten Wagner

Ralph Lipp

Andreas Ohm

Mayk Kresse

Alexander Kuhl

Christian Zurth

Erich Brendel

Peter Kleinebudde

Rolf-Anton Boeggering

Martina Smikalla

Kristina Mueller

Dennis Kvesic

Markus Wirges

Günter Meyer

Daniela Brock

Andreas Meeners

Thomas Volkmer

Sarah Just

Klaus Knop

Frank Bröcker

Jochen Axel Zeitler

Susanne Skrabs

Ulrich Oberdieck

The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin II antagonist and/or at least one diuretic, characterized in that nifedipine or nisoldipine is released in the body in a controlled (modified) manner and the angiotensin II antagonist and/or the diuretic is released rapidly (immediate release (IR)), and also to processes for their preparation, to their use as medicaments and to their use for the prophylaxis, secondary prophylaxis or treatment of disorders.

Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin II antagonist and/or a diuretic

The present invention relates to manufacturing processes for the preparation of a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil and optionally at least one diuretic characterized in that nifedipine is released in the body in a controlled (modified) manner and the candesartan cilexetil is released rapidly (immediate release (IR)) and optionally the diuretic is released rapidly (immediate release (IR)) and the pharmaceutical dosage forms obtainable by these processes.

Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil

Methods for improving solubility and bioavailability of lipophilic compounds are described. Particularly, described are stabilized supersaturated solid solutions, particularly in power from, of lipophilic drugs, such as steroidal molecules.

Stabilised supersaturated solids of lipophilic drugs

The present invention relates to oral solid dosage forms containing a very low dose of estradiol. The dosage forms are formulated in a manner so as to avoid degradation of the estradiol and to minimise the content of polyvinylpyrrolidone, while still achieving similar fast dissolution of the estradiol. The dosage forms are useful in preventing or treating a physical condition in a woman caused by insufficient endogenous levels of estradiol.

Oral solid dosage forms containing a low dose of estradiol

Growing community of inventors

Berlin, Germany

Adrian Funke